Preliminary trial results suggest a path to a safer Alzheimer’s treatment
admin In a blinded analysis that pooled safety data from patients receiving various doses of PMN310...
Health
FDA Refutes Capricor Therapeutics’ Claims of Success in Pivotal Duchenne Muscular Dystrophy Trial.
The Food and Drug Administration said Monday that Capricor Therapeutics’ stem cell treatment for Duchenne...
Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more
On Friday, an FDA advisory panel concluded a pivotal two-day session that could redefine the...
Sarepta names Michael Severino, former Tessera CEO, as new chief executive
The transition marks the end of the Ingram era, a period defined by Sarepta’s transformation...
HIV resurgence is feared as global funding to combat the disease falls 18%
Overall, government funding declined by more than $1.5 billion to $7.3 billion in 2025 —...
Pharma’s drug spending deflection
To understand the current friction between the Pharmaceutical Research and Manufacturers of America (PhRMA) and...
FDA Panel Backs Peptide Compounding Amidst Record-Breaking Measles Outbreaks and Rising Foodborne Illness Concerns
The landscape of American public health is currently navigating a complex intersection of regulatory shifts,...
Pharmalot Coming and Going: Rigel Pharmaceuticals Taps Alison Hannah as New Chief Medical Officer.
The leadership carousel in the biotechnology sector continues to spin at a rapid clip, and...
There are already more U.S. measles cases this year than in all of 2025
The rapid escalation of cases in 2026 has officially made this the nation’s most severe...
FDA Advisory Panel Recommends Compounding Approval for Popular Peptides Amid Growing Political Tensions Over Scientific Oversight.
In a landmark two-day session that may signal a paradigm shift in American drug regulation,...
